ATNF: 180 Life Sciences Corp. Stock

by  •  • Comments Off on ATNF: 180 Life Sciences Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.56
Enterprise Value ($M) 0.64
Book Value ($M) -0.13
Book Value / Share -0.15
Price / Book -12.22
NCAV ($M) -1.75
NCAV / Share -2.05
Price / NCAV -0.89

Profitability (mra)
Return on Invested Capital (ROIC) -21.52
Return on Assets (ROA) -1.34
Return on Equity (ROE) -2.79

Liquidity (mrq)
Quick Ratio 0.72
Current Ratio 0.72

Balance Sheet (mrq) ($M)
Current Assets 3.64
Assets 5.26
Liabilities 5.39
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -13.48
Net Income -19.94
Earnings Per Share Diluted n/a
Earnings Per Share Nonrecurring Common Control Intra Entity Transactions Description n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -10.92
Cash from Investing 0.00
Cash from Financing 5.91

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Armistice Capital, Llc 9.99
2023-04-14 13D/A Feldmann Marc 3.40 -95.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q
2023-08-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT P
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT
2023-04-28 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-19 2,068 18,816 10.99
2024-04-18 19,614 87,287 22.47
2024-04-17 121,996 38,290 318.61
2024-04-16 109,906 99,694 110.24
2024-04-15 5,432 2,163 251.13

(click for more detail)

Similar Companies
ARTL – Artelo Biosciences, Inc. ASNS – Actelis Networks, Inc.
ASRT – Assertio Holdings, Inc. ATOS – Atossa Therapeutics, Inc.
ATXI – Avenue Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io